Burn Wound Clinical Trial
Official title:
A Multicenter, Prospective, Randomized, Comparative Feasibility Study of a Novel Phototherapy System for the Management of Acute Burns
Verified date | January 2020 |
Source | Rogers Sciences Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary purpose of this feasibility study is to evaluate safety and effectiveness in healing outcomes of patients treated with Lumina24TM BLU (treatment), a Continuous Low-Irradiance Phototherapy (CLIP) device, as compared to standard of care (SOC) therapy (control) for the treatment of acute burns.
Status | Not yet recruiting |
Enrollment | 15 |
Est. completion date | August 2021 |
Est. primary completion date | August 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Males or females age > 18 to < 65 - BMI > 20 kg/m2 - Patients anticipated to receive inpatient care for a minimum of 72 hours at the respective medical facility for partial thickness second-degree, deep partial thickness second-degree and/or full thickness third-degree burn wounds. - Patients who have a > 5% to < 50% Total Body Surface Area (TBSA) wound. - Patients are willing and able to adhere to the therapy and protocol. - Female of childbearing potential must be willing to use acceptable methods of contraception. - Patients may or may not have clinical signs and symptoms of burn site infection at baseline. - Subject has read, understood and signed the approved ICF before screening procedures either by the patient or their legally authorized representative. Exclusion Criteria: - Subjects with burns > third-degree (i.e. involvement of deeper tissues, such as muscle, tendons, or bone) - Patients deemed not medically stable by the treating Investigator. - Patients with burn wounds limited to their head or genitalia. - Patients currently enrolled or participating in another investigational device, drug or biological trial that would interfere with the Lumina24TM application. - Patients with inhalation burns. - Patients who are clinically septic. - Patients are pregnant. - Patients on a ventilator, who are undergoing acute fluid resuscitation, are hemodynamically unstable or are deemed 'comfort measures only'. - In the opinion of treating physician, patient not expected to survive beyond 30 days. - Pregnant or lactating status. Pregnancy as determined by a positive pregnancy test at screening or baseline. - Known history of HIV infection, or active Hepatitis B or Hepatitis C infection. - Cancer requiring chemotherapy or radiation within previous 6 months or resection within the last 5 years (other than basal cell carcinoma. - Known chronic renal failure (serum creatine > 2 mg/dL) or chronic liver disease. - Pre-existing medical condition requiring current use of immunosuppressive medication or systemic steroids - Pre-existing medical conditions that would interfere with wound healing (i.e. diabetic patients with Hemoglobin A1c test result > 8%, malignancy, autoimmune disease) - Subjects with psychiatric conditions that are anticipated to result in protocol noncompliance - Chronic illicit drug or alcohol abuse that is anticipated to interfere with patient compliance with the protocol - Subject is incarcerated at the time of screening. |
Country | Name | City | State |
---|---|---|---|
United States | University of Florida | Gainesville | Florida |
Lead Sponsor | Collaborator |
---|---|
Rogers Sciences Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Wound Healing | Percentage area reduction (PAR) of the acute burn wound (SOC control site vs. Lumina24TM BLU treatment site) | up to 28 days | |
Primary | Number of adverse events | Safety measured by incidence of product-related AEs, SAEs, and UADEs | up to 28 days | |
Primary | Microbial load counts (Cohort II only) | Difference of bioburden in/on the burn wound (SOC control site vs. Lumina24TM BLU treatment site) assessed by quantitative analysis of microbial load counts obtained from 3-mm punch biopsies and wound cultures | up to 28 days | |
Secondary | Time to healing | Time to burn wound healing at end of inpatient treatment | 12 months | |
Secondary | Numerical Pain Rating Scale | Difference in pain related to acute burn wounds between SOC control site and Lumina24TM BLU treatment site assessed by patient-reported rating ranging from 0 to 10 (where 0 represents no pain and 10 represents worst possible pain) | 12 months | |
Secondary | Cost-effectiveness | Difference in cost-effectiveness of treatment regime between Lumina24TM BLU and SOC control assessed by difference in sum of costs associated with each treatment regime (including costs of OR visits required, inpatient stay, grafts and/or biologics used) | 12 months | |
Secondary | Patient and Observer Scar Assessment Scale | Difference in healing of hypertrophic scarring between SOC control site and Lumina24TM BLU treatment site assessed by Patient and Observer Scar Assessment Scale | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03948360 -
Safety Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds
|
N/A | |
Completed |
NCT04277182 -
Effect of Propolis Application on Burn Healing
|
N/A | |
Enrolling by invitation |
NCT00978705 -
Clinical Efficacy and Safety of Autologous Cultured Keratinocyte Cell on Severe Burn Wood
|
Phase 3 | |
Withdrawn |
NCT03675568 -
Non-cultured Autologous Keratinocyte Suspension Versus Traditional Split Skin Graft for Burn Wounds Treatment
|
N/A | |
Active, not recruiting |
NCT04828304 -
PLASOMA Ultimate Safety & Efficacy Study
|
N/A | |
Not yet recruiting |
NCT05649332 -
Study to Evaluate the Performance and Safety of the Medical Device Argogen
|
N/A | |
Recruiting |
NCT05593523 -
Fluorescence-based Detection of Inflammation and Necrosis to Inform Surgical Decision-making and Enhance Outcomes
|
||
Completed |
NCT06280053 -
HealiAid in the Treatment of Different Wounds
|
N/A | |
Enrolling by invitation |
NCT06103409 -
MSCs for the Treatment of Burn Wounds
|
Phase 1/Phase 2 | |
Recruiting |
NCT05796492 -
Ultrasound Treatment on Wound Healing Time
|
N/A | |
Enrolling by invitation |
NCT04725071 -
Immunonutrition Supplementation for Improved Burn Wound Healing in Older Adults
|
N/A | |
Suspended |
NCT02577120 -
Wound Healing Endpoint and Recurrence
|
Phase 4 | |
Active, not recruiting |
NCT05341427 -
DEVELOPMENT OF A CLINICAL PREDICTION RULES TO IDENTIFY EFFICACY OF PULSED ELECTROMAGNETIC THERAPY ON BURN WOUND HEALING
|
N/A | |
Completed |
NCT04753723 -
The Use of a Platform Wound Device for Reducing Infection
|
Phase 4 | |
Terminated |
NCT03723590 -
A Clinical Evaluation of an Esterified Hyaluronic Acid Matrix in Burn Patients for STSG
|
N/A | |
Recruiting |
NCT05404191 -
Prediction Rules for Low Level Laser on Burn Wounds
|
N/A | |
Completed |
NCT02982096 -
Study Comparing Healing With Epidermal Fractional Blistergrafting (CellutomeTM) to Acellular Technique
|
N/A |